Investigation of efficacy and safety of switching from basal-bolus therapy to combination therapy with GLP-1 receptor agonist and basal insulin injection in type 2 diabetes

Investigation of efficacy and safety of switching from basal-bolus therapy to combination therapy with GLP-1 receptor agonist and basal insulin injection in type 2 diabetes - JUN-LAN Study 9

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013222

Enrollment

Registered

2014-02-22

Start date

2014-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

Type 2 diabetes treated with basal bolus therapy underwent CGM (day 1). After switching to combination therapy with GLP-1 receptor agonist and basal insulin, 10 and 20 microgram of GLP-1 receptor agon

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) FBS&#8804;130mg/dl and 2hr postprandial glucose &#8804; 250 2)Age&#8805; 20 years old 3)Male and female

Exclusion criteria

Exclusion criteria: 1)hypersensitivity to lixisenatide 2)patient with hypoglycemia 3)patient with serious liver and kidney disease 4)patient with proiferatibe retinopathy 5)during pregnancy and lactation.

Design outcomes

Primary

Measure	Time frame
1.MAGE by CGM 2.Glucose fluctuation by SMBG	—

Secondary

Measure	Time frame
1.change of C-peptide,glucagon and glucose during the meal test 2.frequency of hypoglycemia 3.frequency of adverse events	—

Countries

Japan

Contacts

Public ContactAkio Kanazawa

Juntendo University Graduate School of Medicine Department of Metabolism & Endocrinology

akana@juntendo.ac.jp03-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026